New app aims to help cancer patients spot medication dangers at home

NCT ID NCT07291414

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an online self-monitoring platform helps patients with lung, colorectal, breast, or prostate cancer track medication safety events and concerns while taking oral anticancer drugs at home. Eighty adult patients currently on active cancer treatment will use the platform to log symptoms and issues, and researchers will measure usability, engagement, and health outcomes like emergency visits. The goal is to see if this tool can empower patients to become more vigilant about their medication safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

self-monitoring platform

What this could lead to

If successful, this could provide a simple tool for cancer patients to better track medication side effects and communicate with their care team, potentially reducing emergency visits.

What could go wrong

This is a small, early-stage study focused on usability and feasibility, not on proving health outcomes. The platform may not be widely adopted or show clear benefits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm cancer colorectal carcinoma colorectal neoplasm lung carcinoma lung neoplasm prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Michigan Comprehensive Cancer Center

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact